Likewise, the vast majority of PDA TAMs robustly expressed the M2 marker CLEC7A (Dectin-1), which in concert with its ligand galectin 9 promotes strong immune suppression from macrophages that can be blocked to promote antitumor immunity in PDA (29). The gene discussed is CLEC7A; the disease is Patent ductus arteriosus.